Spironolactone Reduces the Risk of Death in Veterans With Heart Failure With Preserved Ejection Fraction.

ABSTRACT:

Background

Heart failure with preserved ejection fraction (HFpEF) is a complex syndrome increasing in prevalence and affecting millions worldwide but with limited evidence-based therapies. Results from explanatory clinical trials suggest that spironolactone may help to improve outcomes in patients with HFpEF. We sought to investigate the effectiveness of spironolactone in reducing death and hospitalization outcomes for patients with HFpEF in a real-world setting.

Methods and results

We used electronic health records from the US Veterans Affairs (VA) health care system between 2002 and 2012 to identify patients with HFpEF who were followed longitudinally through 2014 using a validated algorithm. Among our HFpEF cohort that is 96% men, 85% White individuals, and aged 74±11 yea

SUBMITTER: Kurgansky KE 

PROVIDER: S-EPMC11292773 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature